Semaglutide vs Tirzepatide vs Retatrutide: One Design, Three Receptor Lists

Semaglutide, tirzepatide and retatrutide are three answers to one engineering problem, and the differences between them are mostly in the receptor list rather than in the molecular scaffolding. All three are long peptides stabilised by the same two tricks. What changes from one to the next is how many of three related receptors each is built to engage, and in what proportion. Read as a series they show a design idea being extended one receptor at a time.

What the three share

Each is a peptide of thirty to forty residues, built on an incretin-family backbone, and each is engineered for persistence in the same two ways. A non-natural residue — 2-aminoisobutyric acid — sits at the position dipeptidyl peptidase-4 would otherwise cleave, removing the enzyme's handle. And a fatty diacid chain is attached through a linker to a lysine side chain, which binds circulating albumin reversibly and shelters the molecule from renal filtration. Those are two of the four standard half-life strategies, and they appear together across the whole class.

The practical consequence is shared too: all three are amphipathic, foam if shaken, and bind hydrophobic plastic at working concentrations — a handling constraint that follows directly from the acylation.

Where they diverge

The second row is the one most often missed. Tirzepatide and retatrutide are not modified GLP-1; they are built on the GIP sequence and engineered to gain GLP-1 activity, which is a different starting point with different consequences for how each receptor is engaged.

Why does the backbone matter if the receptor list is what counts?

Because the receptor list says which receptors are engaged and the backbone says how. A GLP-1-derived peptide engineered to gain GIP activity and a GIP-derived peptide engineered to gain GLP-1 activity can end up with the same two receptors on their list and quite different balances between them. Tirzepatide's reported GIP potency exceeds its GLP-1 potency by a wide margin, which is a property of starting from GIP. The label "dual agonist" hides that asymmetry, and the ratio between the activities is the pharmacology, not the count.

Is retatrutide simply tirzepatide plus glucagon activity?

Only in the crudest sense, and the framing misleads. Adding a third receptor to a dual agonist is not a matter of appending an activity: the residues that confer glucagon receptor engagement sit in the same stretch of sequence that governs the other two, so the whole balance shifts. Retatrutide is a separate molecule with its own ratio across all three receptors, not a superset of tirzepatide. Comparing the two in an assay reading only one receptor will find them similar or different depending entirely on which receptor was chosen.

What the differences mean at the bench

Three consequences follow from the table, and none of them is about which compound is "best".

Assay choice determines the ranking. In a GLP-1 receptor cAMP assay, semaglutide — the selective agonist — may well look the most potent, because its activity is not distributed across other receptors. In a GIP receptor assay it is inert. There is no single readout that ranks the three, and a paper claiming one has chosen its readout.

Albumin in the medium changes everything. All three bind it, so a buffer containing serum sequesters most of the compound and the free concentration bears little relation to the nominal one. Reported EC50 values disagree between papers for this reason before any biology is considered.

Molecular weight differs, so equal mass is not equal molarity. Semaglutide at roughly 4.1 kDa and the other two near 4.8 kDa are not present at the same molar concentration when prepared at the same mg/mL. A comparison at matched mass is a comparison at unmatched molarity.

Why are these three the ones a catalogue carries?

Because they mark the three points on the design series — one, two and three receptors — and because each is a distinct molecule with a distinct literature. Between them they cover the questions a receptor-level study would ask: what selective GLP-1 agonism does, what adding GIP changes, and what adding glucagon changes again. Semaglutide, tirzepatide and retatrutide are supplied separately for that reason; the combination with cagrilintide is a different receptor family altogether.

Does a certificate for these look different?

In the identity panel, yes. The acyl chain and linker add several hundred mass units over the bare sequence, and the Aib substitution adds fourteen, so a theoretical mass calculated from the residue letters alone will not match. The observed mass on the certificate is the number to trust, and for these three it should sit at roughly 4,114, 4,814 and 4,731 daltons respectively. A figure close to a bare-sequence mass would suggest the modification is absent, which would be a different and far less stable molecule under the same name.

Which of the three is the right comparator for the others?

Semaglutide, in most designs, and not because it is the reference in any ranking sense. It is the selective compound: activity at one receptor and none at the other two, so any difference between it and tirzepatide in a given readout can be attributed to GIP activity, and any difference between tirzepatide and retatrutide to glucagon activity. Run in that order, the three isolate one receptor's contribution at a time. Run as a three-way potency contest in a single assay, they produce a ranking that depends on the assay and says nothing about the receptors. The series is informative as a ladder and misleading as a race.

United Peptides supplies these compounds for laboratory and research use only. Nothing here describes clinical use, efficacy or safety in humans or animals. These products are not drugs, foods, supplements or cosmetics, and are not for human or veterinary use.